Molecular Properties
| Parameter | Value |
|---|---|
| Chemical Name | Growth Hormone Releasing Peptide-6 |
| Amino Acid Sequence | His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ |
| Molecular Formula | C₄₆H₅₆N₁₂O₆ |
| Molecular Weight | 872.44 g/mol |
| CAS Number | 87616-84-0 |
| Sequence Length | 6 amino acids (synthetic hexapeptide with D-amino acids) |
| Receptor Target | Growth Hormone Secretagogue Receptor 1a (GHS-R1a) / Ghrelin receptor; CD36 (additional effects) |
Physical Properties
| Property | Specification |
|---|---|
| Appearance | White to off-white lyophilized powder |
| Solubility | Soluble in water or aqueous buffer at ≥1 mg/mL; pH 5.0-7.0 |
| pH (1% solution) | 5.0 - 7.0 |
| Hygroscopicity | Low to moderate; standard desiccated storage |
| Solution Stability | Stable at 4°C for 10-14 days; D-amino acids enhance stability |
Analytical Specifications
| Test | Specification |
|---|---|
| HPLC Purity | ≥98.0% |
| Mass Spectrometry | Confirmed [M+H]⁺ = 872.44 ± 0.5 Da |
| Peptide Content | ≥95% (by amino acid analysis) |
| Endotoxin Level | <1.0 EU/mg |
| Acetate Content | ≤5% |
| TFA Content | ≤0.1% |
| Water Content | ≤6% (Karl Fischer) |
Storage Parameters
| Condition | Specification |
|---|---|
| Lyophilized Storage | -20°C, desiccated |
| Lyophilized Shelf Life | 24-36 months when stored properly |
| Reconstituted Storage | 2-8°C for up to 14 days; -20°C for up to 3 months |
| Analytical Stock Preparation | Dissolve in sterile water or aqueous buffer with gentle vortexing for 30 seconds |
| Freeze-Thaw Cycles | Tolerates up to 5 cycles; D-amino acids provide stability |
| Light Sensitivity | Low; standard laboratory storage acceptable |
In Vitro & Preclinical Model Concentrations
| Experimental Model | Published Concentration / Regimen | Exposure Schedule | Administration Context |
|---|---|---|---|
| In Vitro Pituitary Cell Assays | 10-1000 nM | Acute stimulation (30 min to 2 hours) | Culture media |
| Small Animal Models (Rodent) | 50-500 μg/kg | 1-3x daily | SC or IV in rodent models |
| GH Secretion Studies (Rodent) | 100-300 μg/kg | Single dose or repeated for 7-28 days | SC in rodent models |
| Appetite/Feeding Studies (Rodent) | 200-800 μg/kg | 30-60 min before feeding measurements | SC or IP in rodent models |
Note: Concentrations and animal regimens summarized above are for research reference only. GHRP-6 is intended for laboratory research and is notable for strong appetite-stimulating effects among GHRPs.
Key Research Studies
| Year | Study Focus | Key Findings |
|---|---|---|
| 1984 | Initial discovery and GH-releasing activity | First synthetic hexapeptide GHRP identified by Bowers group; demonstrated potent GH release with EC₅₀ of 0.2-2 nM in vitro; 100-1000x more potent than GHRH on molar basis |
| 1996 | Appetite stimulation and food intake | GHRP-6 (300-600 μg/kg SC) increased food intake by 60-100% within 2 hours in animal models; effect mediated via hypothalamic NPY/AgRP neurons; strongest orexigenic effect among early GHRPs |
| 2002 | CD36 receptor interaction | Identified CD36 (fatty acid translocase) as secondary target for GHRP-6; mediated anti-inflammatory and cardioprotective effects independent of GHS-R1a; Ki ~100-500 nM at CD36 |
| 2008 | Dual receptor mechanism characterization | GHRP-6 effects dissected: GH release via GHS-R1a (blocked by [D-Lys3]-GHRP-6); appetite via GHS-R1a; wound healing and fibrosis effects via CD36; demonstrated unique dual-target pharmacology |
Mechanism of Action
| Biological Pathway | Description |
|---|---|
| GHS-R1a Activation (Primary) | Binds ghrelin receptor (GHS-R1a), Gq-coupled GPCR; high affinity (Kd ~0.5-5 nM); stimulates GH release and appetite |
| GH Secretion | Activates pituitary somatotrophs → PLC/PKC → Ca²⁺ mobilization → GH release; peak GH at 20-40 minutes post-stimulus; pulsatile pattern |
| Appetite Stimulation | Activates arcuate NPY/AgRP neurons; strongest hunger effect in GHRP family; increases ghrelin-like orexigenic signaling; food intake peaks 1-3 hours post-stimulus in rodent models |
| CD36 Receptor Effects | Binds CD36 (moderate affinity); anti-inflammatory actions; modulates fatty acid uptake; cardioprotective and wound healing properties in preclinical models |
| Half-Life | 20-30 minutes (IV/SC); D-amino acids provide peptidase resistance |
Comparative Analysis: GHRP-6 vs GHRP-2
| Parameter | GHRP-6 | GHRP-2 |
|---|---|---|
| Sequence Position 1 | L-His | D-Ala |
| Sequence Position 2 | D-Trp | D-2-Nal |
| GH Release Potency | High (EC₅₀ ~0.2-2 nM) | High (EC₅₀ ~0.1-1 nM) |
| Appetite Stimulation | Very strong (+60-100%) | Strong (+40-60%) |
| CD36 Interaction | Yes (moderate affinity) | Minimal |
| Clinical Development | Research tool | Advanced to diagnostic human trials |
Quality Control Parameters
| Test Method | Acceptance Criteria |
|---|---|
| Appearance (visual) | White to off-white powder; no aggregation or discoloration |
| Chiral Purity | D-amino acids at positions 2 and 5 confirmed; >98% correct stereochemistry |
| RP-HPLC (purity) | Main peak ≥98.0%; no single impurity >0.5% |
| ESI-MS (identity) | [M+H]⁺ = 872.44 ± 0.5 Da confirmed |
| Biological Activity | ≥85% potency vs reference in GH release assay |
Structure-Activity Relationship
| Position | Amino Acid | Structural Role |
|---|---|---|
| 1 | L-His | N-terminal; imidazole ring; pH-dependent charge; distinguishes from GHRP-2 |
| 2 | D-Trp | Critical for receptor binding; D-configuration essential for activity and stability |
| 3 | L-Ala | Conformational spacer; small side chain |
| 4 | L-Trp | Essential for GHS-R1a activation; indole ring interactions |
| 5 | D-Phe | Receptor selectivity; D-configuration prevents degradation |
| 6 | L-Lys-NH₂ | C-terminal; positive charge; amidation absolutely required |
Reported Biological Effects
| Effect Category | Observed Changes | Timeframe |
|---|---|---|
| GH Secretion | Peak GH increase 5-15x baseline; occurs 20-40 min post-stimulus; duration 1-2 hours | Acute (minutes to hours) |
| IGF-1 Elevation | Increased 30-60% with repeated dosing in animal studies; cumulative with chronic administration | 7-14 days |
| Appetite/Food Intake | Increased food intake 60-100% in rodent models; strongest effect in GHRP class; peak 1-3 hours | Acute (1-4 hours) |
| Anti-inflammatory | Reduced inflammatory markers; CD36-mediated effects; cardioprotective/wound healing effects in animal models | 24-72 hours |
Regulatory & Compounding Status (April 2026)
On FDA’s page on bulk drug substances used in compounding, current as of April 22, 2026, GHRP-6 is listed in Category 2 under 503B (bulk drug substances that raise significant safety risks in compounding). GHRP-6 is an unapproved investigational compound and is not approved by the U.S. FDA for human or veterinary therapeutic use. This monograph is intended strictly for laboratory research.
External References
- Bowers CY, et al. Structure-activity relationships of a synthetic pentapeptide that specifically releases growth hormone in vitro. Endocrinology. 1981;108(3):1070-6. https://pubmed.ncbi.nlm.nih.gov/6109621/
- Demers A, et al. Growth hormone-releasing peptides: a potential multifaceted treatment for the heart. Recent Pat Cardiovasc Drug Discov. 2011;6(1):52-9. https://pubmed.ncbi.nlm.nih.gov/21208158/
- National Center for Biotechnology Information. PubChem Compound Summary for GHRP-6. https://pubchem.ncbi.nlm.nih.gov/compound/GHRP-6
